420 with CNW — Sustainability Drives Cannabis Beverage Makers to Adopt Eco-Friendly Packaging

After more than a century of industrialization, we are finally starting to own up to the repercussions of polluting the environment. The world is heating up to a dangerous degree, disrupting planetary cycles and causing extreme weather conditions around the globe. While the drive for sustainability and renewability didn’t pick up much steam before the 2010s, more and more companies are striving to reduce their carbon footprints as people become more conscious of the environmental effects of their favorite products. America’s state-legal cannabis industry hasn’t been left behind, with players that make cannabis beverages ditching traditional packaging options for ecofriendly alternatives.

Consumers, especially from the younger generations, are more cognizant of climate change, and this is frequently reflected in their buying habits. Katie Simmons, marketing director for Pactiv Evergreen, says consumers are increasingly turning their attention to healthy, sustainable products, and this extends to beverage packaging.

Recyclability and renewability are top priorities when it comes to beverage packaging considering how wasteful and harmful traditional beverage packaging such as glass and plastic can be. As a whole, the beverage industry is changing to stay ahead of both consumer demand and legislation, according to Peter Gonclaves, vice president of marketing at Tetra Pak.

Cannabis beverages are a relatively new segment of the marijuana industry, partly because the technology needed to make high-quality cannabis-infused drinks has taken time to perfect. Even so, the global cannabis beverages market is projected to be worth $2 billion by 2026, and companies that hope to succeed will have to make sustainability a major part of their plans. Not only will this allow them to attract environment-conscious customers in droves, but it will also help them reduce their carbon footprints and meet increasingly strict emission standards. Using sustainable packaging is an effective way to do this because it reduces the amount of overall waste at the source and lessens the strain recycling facilities are under. Tetra Pak, for instance, has launched a program that develops cartons using carbon-neutral, fully renewable, and fully recyclable plant-based materials.

Brent Haynam, commercial engineering manager for Scholle IPN, notes that sustainable packaging doesn’t just further recycling goals. “Bag-in-box” and pouch packaging for beverages can reduce source material weight by as much as 90%, he says. For instance, a player in the wine industry can ship more than 100,000 empty bag-in-box packages compared to only 34,000 glass bottles in a truck, resulting in significant savings as well as helping to preserve the environment.

Companies such as BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) that walk the talk of environmental consciousness are set to reap big as less ecologically responsible companies are gradually shunned by consumers.

NOTE TO INVESTORS: The latest news and updates relating to BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) are available in the company’s newsroom at http://cnw.fm/BVNNF

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Marijuana Company of America Inc. (MCOA) Announces Plans to Launch VapeTV US

Marijuana Company of America (OTC: MCOA), a diversified holding company with operations and investments throughout the cannabis industry, today announced its entry into a non-binding letter of intent (“LOI”) for the formation of a new in-store advertising business to be called VapeTV US Inc. According to the update, MCOA’s wholly owned distribution company, cDistro Inc., will own 25% of the VapeTV US business, partnering with VapeTV Ltd. of the United Kingdom and Jasleen Enterprises LLC, the owner of Vapor Maven. “We are excited to initiate the U.S. market version of the highly successful and lucrative VapeTV business,” said Mike Shaw, the founder of VapeTV UK. “By launching with Vapor Maven’s nearly 200 retail locations and by leveraging cDistro’s active customer database of more than 65,000 retail vape stores in the U.S., we anticipate an accelerated delivery of VapeTV advertising content to U.S. consumers. We believe that the high level of competition among the thousands of individual smoke, vape and CBD brands vying to sell in the U.S. will result in a high demand for the in-store media advertising space and content VapeTV US plans to provide.”

To view the full press release, visit https://cnw.fm/TYGFG

About Marijuana Company of America Inc.

Marijuana Company of America operates and invests in the cannabis sector directly. The company’s operations include C-Distro, one of the fastest growing distribution companies in the THC, Hemp and CBD cannabis industries, hempsmart(TM), a premium CBD company, and a Salinas, California-based cannabis nursery cultivation facility that is a cultivator and distributor utilizing its own growing systems to produce desirable cannabis clones. The company’s core mission is to leverage its experience and access to capital to identify and invest in acquisitions with unique growth potential. For more information, visit www.MarijuanaCompanyofAmerica.com.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Announces Strategic Engagement of MZ Group

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) today announced its engagement of international investor relations specialists MZ Group to lead a comprehensive strategic investor relations and financial communications program across all key markets. The partnership with MZ represents an investment in BevCanna’s go-forward growth strategy as the company rapidly accelerates its evolution into a diversified health and wellness company. “Cannabis is an emerging leader within the overall $4.5 trillion wellness market, with the product market projected to reach $90.4 billion by 2026, according to MarketsandMarkets,” said Ted Haberfield, chairman and president of MZ Group North America. “BevCanna leverages proprietary and patented technology to produce premium tasting, water-soluble cannabinoid infusions using THC and CBD from both cannabis and hemp. The company’s expertise, world-class infrastructure and proven technology enables the development and launch of premium, innovative, cannabis-infused beverages that cater to the next generation of cannabis consumer.”

To view the full press release, visit https://cnw.fm/js3V3

About BevCanna Enterprises Inc.

BevCanna Enterprises is a diversified health and wellness beverage and natural products company. BevCanna develops and manufactures a range of alkaline, plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. With decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale, the team demonstrates an expertise unmatched in the nutraceutical and cannabis-infused beverage categories. Based in British Columbia, Canada, BevCanna owns a pristine alkaline spring water aquifer and a world–class 40,000–square–foot, HACCP-certified manufacturing facility, with a bottling capacity of up to 210 million bottles annually. BevCanna’s extensive distribution network includes more than 3,000 points of retail distribution through its market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network, and a partnership with top U.S. cannabis beverage company Keef Brands. For more information about the company, visit www.BevCanna.com.

NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://cnw.fm/BVNNF

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Expand Hypertension Clinical Program Through Most Ambitious Study to Date

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced a significant new study to expand its hypertension clinical program. In addition, the company provided updates on three ongoing human clinical studies evaluating its proprietary DehydraTECH-CBD for potentially treating hypertension and heart disease. “HYPER-H21-4 is the most ambitious study Lexaria has ever undertaken and is enabled from the successful outcomes from our other 2021 human hypertension studies,” said Lexaria CEO Chris Bunka in the news release. “Outcomes from this study could support Lexaria’s goals related to pursuit of regulatory approvals for DehydraTECH-CBD for potential use as a treatment for high blood pressure.”

To view the full press release, visit https://cnw.fm/GVGwq

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1-2 hours to minutes and mask unwanted tastes; it is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Senate Committee Asks State Department to Account for Funds Spent on Drug War

A recent report filed by top senators has asked the State Department to explain how the billions in funding that was injected into various counter-narcotics programs across Latin America were used, as these programs haven’t yielded results. The report also calls out the federal government over the failed war on drugs.

The report is part of the bill to finance the federal government that Chairman Patrick Leahy of the Senate Appropriations Committee introduced a couple of days ago.

The panel stated that the incidence of corruption and violence related to drug trafficking in Latin America has increased steadily since the 1980s when various counter-narcotics programs were introduced. The use and availability of illicit drugs in the United States is also high. The panel noted that despite these failures, the strategies used by different U.S. administrations since the inception of these programs remain unchanged.

The report directs the secretary of state to compile and present a report that assesses the reasons why prior efforts haven’t met the expectations as well as the cost-benefit analysis of previous counter-narcotics initiatives in Mexico, Central America, Colombia, Bolivia and Peru.

The committee is also seeking a description of the objectives and projected results of the present strategy, how the present strategy is different from past efforts and any necessary changes in the United States domestic counter-narcotics policies. This, it stated, would allow strategies that decrease the production and trafficking of illegal drugs and related corruption and violence in Latin America to succeed.

This draft Appropriations Committee report will be attached to the 2022 fiscal year spending bill for the Department of State, Foreign Operations and Related Programs. It remains unclear when the measures will be considered and officially approved by the panel.

If the measure is enacted, it would allow Washington D.C. to legalize recreational cannabis sales. It would also encourage the development of technologies that can identify THC-impaired driving and request the federal government to reconsider policies that require employees be fired for marijuana use. In addition, the measure criticizes the current restrictive system for classifying drugs, which hinders scientific research on marijuana.

Rep. Alexandria Ocasio-Cortez introduced a similar amendment in the House’s version of the spending legislation, which was recently passed. The measure calls for banning the use of funds for aerial fumigation on illicit crops in Colombia. Aerial fumigation has been widely criticized by human rights and reform advocates.

The step taken by the Senate committee could trigger a rethink of the country’s drug policies and maybe even kick-start a process through which cannabis may be rescheduled federally, ending one of the biggest hurdles that the industry and its sector players, such as Hero Technologies Inc. (OTC: HENC), have had to navigate.

NOTE TO INVESTORS: The latest news and updates relating to Hero Technologies Inc. (OTC: HENC) are available in the company’s newsroom at https://cnw.fm/HENC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Lung Cancer Case Report Triggers Calls for Additional Research on Cannabidiol

Although cannabidiol (“CBD”) has grown extremely popular over the past couple of years thanks to anecdotal user claims of medical efficacy, most scientists have been reluctant to say anything conclusive until they carry out more in-depth research. Users have claimed that CBD can be effective against pain, anxiety, depression, and insomnia; in limited circles, some even claim that the hemp extract can kill cancer cells. But as the research on CBD’s potential benefits and risks is limited and in its infancy, experts have cautioned against using CBD as an alternative to prescribed medication, especially when life-threatening conditions like cancer are concerned. However, the curious case of a woman with lung cancer has underscored the need for more in-depth research on CBD as a potential treatment for cancer.

According to a newly published report in “BMJ Case Reports,” a female patient in her 80s who suffered from cancer may have benefited from using CBD oil. An active smoker, the patient smoked at least one pack per week and was afflicted with several health conditions, including high blood pressure and COPD. She was also diagnosed with non-small cell lung cancer after doctors discovered a 41mm malignant tumor in her lung.

After that 2018 diagnosis, the patient refused conventional treatment and only came in for regular healthcare monitoring as well as CT scans every half year. Although the type of cancer she suffered from had an estimated half-year survival rate sans treatment, the patient was still alive as of February 2021, and her tumor had decreased by 76% (to 10mm) despite refusing treatment.

In 2019, she revealed that she had started taking around 0.5ml of CBD oil two to three times a day, and details by the supplier show that the CBD oil had 20% CBD, 19.5% THC and 24% THCA. It seems as if the tumor shrunk without the help of conventional cancer treatments such as chemotherapy, radiation and surgery, and despite the fact that the patient continued to smoke during this period, she did not experience any prescription or lifestyle changes. The report’s authors suggest that while there may indeed be a connection between CBD oil consumption and tumor regression, more research is needed for them to fully understand the relationship,

Currently, some cancer patients use cannabis not to treat their tumors but to alleviate the side effects of the condition and cancer treatment, including nausea, vomiting, insomnia and lack of appetite. Dr. James B. Yu, a radiation oncologist at Yale Medicine and a therapeutic radiology professor at the School of Medicine at Yale University, also notes that this singular case should not be seen as concrete evidence of CBD’s cancer treating abilities because there are cases of lung cancer regressing without conventional treatment.

This case study adds to the existing limited verifiable data about the possible benefits of various cannabinoids such as CBD, and it makes a case for the FDA to pass enabling policies creating uniform federal regulations for CBD product makers such as Simply Sonoma Inc. and manufacturers of other cannabis-based products.

NOTE TO INVESTORS: The latest news and updates relating to Simply Sonoma Inc. are available in the company’s newsroom at https://cnw.fm/Sonoma

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lift&Co. Expo 2021 to Shine the Spotlight on Surprises and Ah-Ha! Moments

Lift&Co. Expo, Canada’s No. 1 cannabis conference and trade show, has surprises in store for its upcoming event. The expo, slated to take place at the Metro Toronto Convention Centre from Nov. 18-21, 2021, is legendary for its high-energy, immersive experience. With the debut of the Lift Psychedelics Business Summit and the Lift Cannabis Business Conference and Lift&Co. Expo Industry & Consumer Days trade show rounding out the agenda, the highly anticipated event is raising the bar for this year’s return. “After a necessary hiatus last year, our team is overflowing with new attractions and innovations as we bring everyone safely together again. But you don’t have to take my word for it,” said Shawn Pierce, president of strategic events, meetings and incentives at event producer, MCI. “We’re having fun here, hinting at all the new elements we’ve planned, but Lift&Co. Expo must be experienced live to truly understand what all the excitement is about.” To view the full press release, visit https://cnw.fm/LqYYP ABOUT MCI MCI is the global leader in engaging and activating audiences. Its business is founded on a simple human insight: When people come together, magic happens. Since 1987, MCI has been bringing people together through inspiring meetings, events, congresses and association or community management. MCI helps organizations harness the power of community by applying its strategic engagement and activation solutions to build unforgettable online and offline experiences that foster change, inspire, educate and enhance business performance. MCI is an independently owned company headquartered in Geneva, Switzerland, and boasts a global presence with 2,500+ professionals in 61 offices and 31 countries who work with clients across Europe, the Americas, Asia-Pacific, India, and the Middle East. For more information, visit www.MCI-Group.com. About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CannabisNewsWire (CNW) Denver, Colorado www.CannabisNewsWire.com 303.498.7722 Office Editor@CannabisNewsWire.com CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — New York Cannabis Regulators to Allow Patients to Grow Medical Cannabis

The Cannabis Control Board in the state of New York has voted to allow medical marijuana patients to grow marijuana for personal use. The cannabis regulators plan to file the proposed regulations, which will permit patients who meet the criteria to grow up to six plants, either outdoors or indoors, for their own therapeutic use.

Once the regulations have been published, the public will be afforded a 60-day comment period. After this, the board will review these comments and make any amendments they deem necessary, after which the regulations will be filed officially in order to take effect.

The chair of the Cannabis Control Board, former Assemblywoman Tremaine Wright, stated that the board was proud to present these proposed measures. She explained that allowing patients to cultivate medical marijuana at home would offer them a cost-effective way to acquire marijuana while also allowing them to establish a set of standards that will govern the activities associated with the personal cultivation of marijuana. In its presentation, the board stated that a duty on patients to take reasonable measures to make sure none of their marijuana plants wasn’t readily accessible to individuals who are under the age of 21 would be imposed.

Caregivers for patients who have cognitive or physical impairments that hinder them from growing marijuana or are yet to reach 21 years of age, are also allowed to grow up to six plants on their patients’ behalf. However, the rules also stipulate that landlords have the option of barring tenants from growing cannabis on their properties. Additionally, recreational marijuana consumers are still not allowed to grow their own cannabis until adult-use sales commence.

The Office of Cannabis Management also gave an update on efforts to expunge marijuana records. Thus far, more than 40 expungements for cases associated with cannabis possession have been done. The office notes that about 203,000 cannabis-related charges are also in the process of being expunged or sealed. This number adds to the more than 197,000 sealings accomplished as part of the 2019 expungement measure.

Currently, the Cannabis Control Board oversees the independent Office of Cannabis Management in the New York State Liquor Authority. The state’s liquor authority is also responsible for regulating the hemp and medical cannabis industries in the state of New York.

At the moment, individuals aged 21 and above can possess up to three ounces of marijuana in the state, which is equal to about 24 grams. In addition to this, they can smoke cannabis anywhere tobacco can be smoked.

As more people warm up to medical marijuana, more of them will be exposed to enabling technologies such as the IoT dose-measuring devices made by RYAH Group Inc. (CSE: RYAH), which can bring precision to the use of smokable cannabis products. Such devices could potentially improve patient outcomes.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — NIDA Tells Congress Drug Scheduling Is Hindering Cannabis Research

Marijuana’s federal classification as a Schedule I controlled substance has consistently been a thorn in the plant’s side, especially as more states have chosen to legalize it in various capacities. With the drug more accessible to the public than it has ever been thanks to state cannabis reform, a growing number of people have been using cannabis either medically or recreationally.

As cannabis becomes even more popular among the masses, most experts agree that the hype around it and its purported medical abilities has far outpaced the science and that more research on marijuana’s potential benefits and risks is needed. However, its classification as an illegal drug by the federal government has been a major hindrance to more comprehensive cannabis research, a top federal agency recently told Congress.

In a report submitted to the House and Senate Appropriations Committee, the National Institute on Drug Abuse (NIDA) outlined the barriers researchers face when they try to study Schedule I substances such as cannabis, including the “administratively complex” process they have to go through before they can receive authorization from the Drug Enforcement Administration.

It can take researchers more than a year to obtain a new registration, the report said, and it can take quite a while to modify a registration as well. Furthermore, different interpretations of the Schedule I registration requirements by research institutions and local DEA field officers coupled with different federal and state registration requirements make researching cannabis even more of a headache.

With all these challenges, the report says, researchers’ efforts to study cannabis more closely are often deterred or prevented. For instance, scientists who want to make a relatively minor change to their registration, such as adjusting the quantity of cannabis being used, have to re-register with the DEA. In some cases, the DEA has required that researchers obtain several registrations for each physical site where they study Schedule I drugs.

On top of listing registration-related barriers to cannabis research, the report mentioned how researchers are currently limited to using cannabis grown at the University of Mississippi. For quite a while, researchers have said that the marijuana cultivated in this facility is extremely low quality, tends to be contaminated with mold and barely has any THC in it.

As cannabis use becomes more prevalent, these barriers to research present a significant health crisis. There are millions of medical marijuana patients in the country, not to mention all the people who use cannabis recreationally, and the lack of concrete scientific data on its potential benefits and risks poses a dangerous public health risk.

Fortunately, things seem to be improving. A bipartisan group of House members recently filed a bill that would streamline the research registration process and allow researchers to study cannabis sourced from dispensaries. In addition, lawmakers are working on large-scale infrastructure legislation that would provide a framework for scientists to study the marijuana consumers are actually purchasing.

Not only is the current scheduling hindering research, it is also standing in the way of the growth of the industry. For example, when companies such as American Cannabis Partners are unable to access mainstream banks, they are forced to grow at a slower pace than might have been possible if they could obtain loans from federally regulated financial institutions.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has begun a new study, EPIL-A21-1,designed to evaluate whether its DehydraTECH(TM)-CBD (“CBD”) indicates superior ability to reduce seizure activity compared to both generic cannabidiol and Epidiolex. Epidiolex is the only CBD medication approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two rare and severe forms of pediatric epilepsy. Among those involved in the study are respirology and neurobiology experts. According to the announcement, the team of investigators will carefully analyze how DehydraTECH-CBD compares with Epidiolex in treating seizures. LEXX noted that the company developed its seizure program because of the significant gains in systemic delivery and brain uptake that had been seen repeatedly in its own studies as well as other studies comparing DehydraTECH-CBD with concentration-matched controls. Lexaria also announced that it has received its first patent award for DehydraTECH in Mexico as well as another patent in Japan; the Mexico award protects the proprietary drug-delivery system for use with cannabinoids and nicotine while the Japan patent covers the use of DehydraTECH utilizing nonpsychoactive cannabinoids, nicotine, vitamins or nonsteroidal anti-inflammatory (“NSAID”) substances. The Japan award is the fifth patent the company has been awarded in 2021. The company currently has 23 granted patents from the United States, Australia, the European Union, India, Japan and Mexico that protect DehydraTECH.

To view the full press release, visit https://cnw.fm/0OoFx

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption of cannabinoids and nicotine by 5 to 10 times as well as reduce time of onset from one to two hours to minutes and mask unwanted tastes. The delivery systems are also being evaluated for orally administered, anti-viral drugs and nonsteroidal, anti-inflammatory drugs (NSAIDs) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.